Advanced biomimetic nanomedicines for cell-based therapeutics: prospects and challenges Authors: Ying Wang, Liangliang Zhao, Ying Zou, Lili Nie Published: 2026 ABSTRACT AbstractAdvanced biomimetic nanomedicines offer cell-based therapeutics to mimic biological behaviors for improved targeting, immune evasion, and integration with living cells. This review critically examines recent innovations in biomimetic nanocarriers especially leveraging from cell membranes, membrane proteins, or native cellular structures to support cell therapies. These systems aid in prolonging circulation, reducing immunogenicity, and directing therapeutic cells to disease sites. Membrane-coated nanoparticles, metal–phenolic network-based nanovaccines, and stem-cell-membrane-coated carriers have therapeutic potential but challenges of manufacturing, scalability, quality control, in vivo stability, and regulatory barriers are present. To overcome these challenges, substituted hybrid membrane formulations, bio-responsive release mechanisms, and modular design are adopted. This review aims to guide future research toward clinical viable biomimetic nanomedicines for cell-based therapies.Keywords: Biomimetic nanomedicine, Cell-based therapeutics, Drug delivery systems, Immune cell-targeted nanomedicine Introduction Concept of Biomimetics was first introduced by Otto Schmitt in 1957, and it involves designing synthetic materials and systems that imitate structures, functions, and strategies found in nature [1]. In nanomedicine, this idea has expanded to engineer nanomaterials replicating the physicochemical and functional properties of cells and tissues [2]. Modern biomimetic nanomaterials rely on mechanisms such as self-assembly, molecular recognition, and incorporation of biopolymers or bio composites, enabling them to closely mimic biological behaviors even when synthesized via non-natural methods such as electrospinning or plasma techniques [3]. Over the past few decades, biomimetic approaches have transformed drug-delivery systems, tissue engineering, and theranostics. Early nanoparticles (NPs) were designed to be “biologically inert,” avoiding unwanted immune interactions [4]. Later generations introduced ligand-based targeting strategies to improve specificity toward diseased tissues. The most advanced designs now integrate natural cell-membrane components onto synthetic cores, enabling NPs to replicate the surface phenotype of native cells and significantly enhance circulation time, target recognition, and biocompatibility [5]. Recent biomimetic platforms generally follow three strategies i.e. synthetic NPs functionalized with biological targeting ligands, NPs coated with whole cell membranes, and liposomes enriched with cell-membrane proteins [6, 7]. These novel applications in inflammatory and vascular diseases enable macrophage, platelet and erythrocyte membranes to guide NPs to disease site to ensure accurate localization [8]. These systems are prepared by isolating cell membranes, producing nanoscale vesicles, and coating or encasing therapeutic NPs cores inside them [9]. According to the latest developments, the biomimetic nanomaterials can be divided into three types: the materials that have biomimetic structural elements (membrane-protein-based liposomes), the materials that are synthesized using biomimetic methods (formation of magnetosomes), and hybrid systems comprising the real biogenic components (such as erythrocyte membranes) (Fig. 1). These categories comprise magnetic, metallic, polymer, ceramic and multicomponent hybrid nanostructures with distinct functional benefits [10]. Different biomimetic nanoparticles. Adapted from the reference [11] under Creative Commons Attribution 4.0 (CC BY 4.0) Biomimetic nanomaterials are nanosystems that mimic natural structures and their interactions. These are potent platforms of cell-based therapeutics because of their capability to enhance drug delivery, biodistribution and targeted therapy [12, 13]. Previous approaches in nanomedicine mainly revolved around the development of NPs that were not able to induce the immune responses. Recent developments the focused biomimetic NPs particularly engineered using natural cell membranes [14, 15]. These systems take advantage of the biological communication pathways by imitating surface features and functional behaviors of cells native to the body [16]. Broad biomimetic platforms have been engineered with whole cells, cell ghosts or isolated membrane proteins to more accurately recapitulate natural cellular interactions [17]. These designs increase stability of NPs to circulatory systems, minimize rate of immune clearance, and eventually facilitate drug delivery [18]. By presenting authentic cell-derived components and signaling molecules, biomimetic NPs can also engage directly with immune cells, modulate local immune responses, and overcome biological barriers that limit performance of conventional NPs [19]. The nano- bio interface forms a dynamic interface where NPs come into direct contact with biological components having implication on their in vivo fate. The physicochemical properties like size, shape, surface charge, and functionalization determine cellular and protein communication of NPs, that immerses biological recognition and response. Communication at this interface can be categorized into two, one being in the systemic circulation and the other in target tissue [20, 21]. NPs adsorb on surface of circulating protiens creating protein corona (Fig. 2). Intermediate-sized particles (80 to 120-nm) adsorb fewer opsonins than larger particles (170 to 240-nm), leading to slower clearance and longer circulation in rodent models.Particles less than 5 to 8 nm are cleared faster by kidneys and particles (over 200 nm) may trapped by splenic macrophages. Shape also influences outcomes. Non-spherical particles often show different corona compositions. Prolonged circulation duration for non-spherical particles are observed as compared with spheres. These effects also vary with material, and surface chemistry. Surface chemistry affects protein adsorption and immune recognition. Hydrophilic near-neutral surfaces like PEGylation or zwitterionic layers decrease opsonin binding and phagocytic uptake and strongly charged or hydrophobic surfaces are cleared faster. In vivo fate is determined by material composition and mechanical properties. Biodegradable polymer- or lipid-based NPs forms excretable metabolites, but non-degradable inorganic cores (gold, silica) may accumulate in organs [22–26]. Schematic illustration of interaction of nanoparticles with biological. Interactions like hydrophilic and hydrophobic forces, hydrogen bonding, and electrostatic attractions, affect adsorption of proteins and the creation of the protein corona on the surface of NPs. This formation of protein corona is unfolding and stretching of native protein structure on binding of protein to NP and may change protein function and affect immune recognition. These molecular interactions influence on NP biological identity, biodistribution, immune clearance and their therapeutic efficacy. Adapted from the reference [27] under Creative Commons Attribution 4.0 (CC BY 4.0) NPs uptake is also regulated by scavenger receptors (SR-B1, CD36, MARCO) present on the macrophages, endothelial cells, and the target tissue cells. Although these receptors are capable of promoting targeted accumulation through SR-B1 to tumors of ovaries or colorectum, and result in proinflammatory reactions. In addition to circulation, nano- bio interface allows NPs to interact with immune cells in the disease regions. NPs able to control immune responses by presenting surface molecules that resemble native antigen-presenting cells (APCs) to induce cytotoxic T cells against tumors or growing regulatory T cells in autoimmune disease situations. NPs shape and morphology also determine immune engagement. Ellipsoidal or nanotube shape is better than sphere in imitating APCs and thus increasing ligand-receptor interaction with the T cells. With these design principles, NPs can provide accurate immunomodulatory cues making the nano- bio interface suitable in therapeutic intervention [28–30]. The review discusses biomimetic rationale behind these systems, how they replicate characteristics of natural cells and overcoming challenges in conventional nanomedicine, including immune clearance and limited biofunctionality. Biomimetic soft systems Biomimetic soft systems replicate life-like behaviors. Living systems are characterized by compartmentalization, organization, efficient biochemical reactions and stabilization of complex enzymatic networks [31]. Mitochondria, endosomes and nuclei which surround functional molecules and control selective transportation. Such compartmentalization has inspired the formation of artificial soft systems, including liposomes, proteinosomes, coacervates, polymersomes and capsosomes all of which have their own distinct benefits in context of synthetic biology, drug delivery and microreactor applications [17, 32]. Giant liposomes These are earliest synthetic counterparts of biological compartments, which are aqueous cores coated by lipid bi-layer. They encloses enzymes, nucleic acid and small molecules as artificial cells [33]. Liposomes vary in size between nanometer-sized vesicles (SUVs, LUVs) and giant unilamellar vesicles (GUVs) of 1 μm (comparable to eukaryotic cells). Liposome formation controlled by using different techniques such as thin-film hydration, electroformation, microfluidics, and pulsed jetting [34]. Incorporating membrane proteins α-hemolysin, OmpF and DNA, nanopores enhances permeability which enables controlled molecular transport. Although these approaches are stable but high encapsulation efficiency and retention of biofunctionality in fabricated conditions have been challanging [35, 36]. Proteinosomes Proteins as building blocks of biomimetic compartments are employed in proteinosomes. They were made of natural amphiphilic proteins (lipase) or artificial protein-polymer conjugates, by self-assembly or layer-by-layer deposition [17, 37]. Their semi membrane is chemically/enzymatically tuned to permit selective translocation of macromolecules (10–71 kDA) [38]. Hybrid proteinosomes incorporating inorganic NPs or polymers expand functionality. They enable interfacial catalysis, photoluminescence and possess antibacterial properties. These features make them valuable for bottom-up, bioinspired microreactors, and therapeutic delivery [39, 40]. Coacervates Coacervates are membrane-free vesicles created by electrostatic interactions between oppositely charged macromolecules [41]. They are simple protocell models simulating intracellular environment of high density. They have ability react to multienzyme reactions with higher efficiency. It is an entropy-driven process occurs due to counterion release. Membrane free coacervates are able to selectively sequester molecules and endure changes in environment. New developments are semipermeable coacervates stabilised by polymers, which permit spatial isolation of incompatible enzymes and proto-organelles. and have been shown to effectively recapitulate eukaryotic subcellular organisation. Polymers such as PEG and dextran used as aqueous two-phase systems (ATPS) to provide biocompatible, size-selective and compartmentalized platform to enrich biomolecules [41, 42]. Polymersomes These are self-assembled vesicles made of amphiphilic copolymers having tunable size, shape, permeability, and biofunctionalization. They are amphiphilic block copolymer (BCP) membranes that resemble lipid bilayers but are more chemically stable and versatile, allowing them to be used in drug delivery, microreactors and synthetic cell models [43]. Enzymes and other biomacromolecules can be encapsulated within polymersomes. Membrane permeability designed in various forms including polymer packing size-selective diffusion, membrane protein insertion (OmpF, Aquaporin Z, melittin), or stimulus-responsive moieties can be incorporated, responding to pH, temperature, redox conditions or light [44]. These properties enable regulated influx and efflux of substrates by enabling inter- and intra-compartmental communication and signaling cascades of synthetic organelle functions. Thin-film rehydration and solvent-switch loading techniques can be used to load enzymatic cargos. Polymersomes may also be subjected to shape changes by osmotic imbalance from spherical geometries to create tubes or bowl-shaped stomatocytes. Polymersomes which are asymmetrically distended enhance facilitation of encapsulation of enzymes, mobility and other advanced biomimetic functions [45, 46]. Mild encapsulation approaches under aqueous or low-stress conditions employed which are based on controlled osmotic or solvent-switch methods with gradual changes in solvent composition or osmotic pressure. These changes induce membrane rearrangement without disrupting vesicle integrity and are reported to retain enzymatic activity during morphological transitions highlighting its importance in preserving biomolecular functions [47]. Capsosomes and polymeric capsules Different multicompartment systems of soft systems have been created such as vesosomes (liposomes in liposomes), proteinosomes-in-proteinosomes, polymersomes-in-polymersomes, and polymersomes-in-polymer capsules. Capsosomes offer high stability of polymeric shell of capsosomes with high permeability of the encased liposomal subcompartments. They are prepared by adsorbing liposomes onto polylysine-coated silica template, by alternating polymer and liposomes. Up to 160,000 liposomes can be incorporated into a capsule, which permits the space separation of the enzymes to allow parallel or tandem reactions. Liposomal sub compartments can be stabilized and permeabilized by incorporation of cholesterol, or addition of surfactants to initiate cargo release or enzyme cascades. Layer-by-Layer (LbL) polymeric capsules are made through successive deposition of oppositely charged polymers onto sacrificial templates to control surface charge film thickness and permeability [48]. Incorporation of stimuli-responsive polymers like PNIPAAm-b-PMAA-co-DMIBM allows pH and temperature-controlled modulation of enzyme activity stabilized by crosslinking [49, 50]. Design strategies for biomimetic nanomedicines Monotypic cell membrane-coated NPs Red blood cell membrane-coated NPs (RBCNPs) RBCs have long circulation half-life (~ 120 days). RBC membrane-coated NPs leverage intrinsic properties of biodegradability, and biocompatibility to enhance therapeutic efficacy [51]. CD47 membrane protein on RBCs interacts with signal-regulatory protein alpha (SIRPα) on macrophages, delivering “do not eat me” signal that prevents phagocytosis and extends circulation time. C8-binding protein (C8bp), complement receptor 1 (CR1), decay-accelerating factor (DAF), and CD59 are other proteins that provide protection against complement-mediated attacks. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) analysis of protein-normalized RBC-NPs demonstrated preservation of overall membrane protein profiles comparable to native RBC ghosts. Western blotting further confirmed the presence of key self-markers such as CD47 on the nanoparticle surface. In addition, label-free quantitative proteomics using LC–MS/MS provided a comprehensive characterization of retained membrane proteins, verifying their presence and relative abundance after coating. These approaches collectively support that critical membrane proteins are retained post-fabrication and contribute to functional mimicry, particularly in immune evasion and prolonged circulation [52]. In vivo studies demonstrate that RBC-NPs exhibit significantly prolonged circulation compared with PEGylated or uncoated NPs, thereby enhancing drug delivery efficiency. RBC membranes also neutralize bacterial exotoxins, providing detoxification and antibacterial benefits. Furthermore, simplicity of extracting membranes from anucleate RBCs allows cost-effective mass production, making RBCNPs appropriate candidates for clinical translation in drug delivery, antibacterial therapy, and detoxification applications [53–55]. RBC membrane-coated polymeric NPs loaded with chemotherapeutics exhibit significantly prolonged circulation and reduced immune clearance due to CD47-mediated signaling, resulting in enhanced drug bioavailability. Limitations of potential membrane protein denaturation during processing and lack of active targeting restrict their application in site-specific therapies [56]. As summarized in Table 1, key characteristics and functional attributes of membrane-coated NPs systems. Also, an overview of current biomimetic toolkit, including source cell types, fabrication strategies, membrane protein functions, and delivered cargoes are shown in Fig. 3. Table 1Overview of different cell-membrane–coated nanoparticle systems, including membrane sources, and their corresponding therapeutic and diagnostic applicationsMembrane SourceCoreCargo / DrugTargetApplicationLimitationEvidence Level / RefErythrocyteHSA particles, magnetic nanostructures, PLGA, chitosan carriers, PFC-integrated PLGAICG, PFTBA, DOX/PTXImmune evasion, prolonged circulationPhototherapy, toxin neutralization, chemotherapy, radiotherapy enhancement, tumor imagingLimited active targeting; possible protein denaturation during coating[57, 58]PlateletPLGA, silicon carriers, verteporfin-PLGA, melanin-based carriersDocetaxel, vancomycin, TRAIL, DOXSite-specific adhesion via platelet receptorsCancer therapy, infection targeting, phototherapyRisk of thrombosis / unintended platelet activation (mitigated with functional assays)[59, 60]LeukocyteJanus nanoarchitectures, porous Si NPsN/AImmune evasion, tumor endothelium recognitionPhotothermal tumor ablation, drug deliveryVariable circulation depending on membrane source[61, 62]NeutrophilPLGACarfilzomibHoming to pre-metastatic niches, CTC captureMetastasis inhibition, CTC targetingLimited cargo capacity, short-term circulation[63, 64]NK-cellFusogenic liposomesDOXTumor recognition via NK receptor interactionsPrecision drug delivery to tumorsComplex isolation; potential immunogenicity[65, 66]Cytotoxic T-cellPLGAPTXTumor antigen recognitionTumor therapyLimited scalability[67, 68]MacrophageUpconversion NPs, gold-nanoshell silica hybrids, emtansine-liposomal constructs, insulin-targeted polymersVarious chemotherapeutics, photothermal agentsImmune evasion, pathogen recognition, tumor endothelium targetingCancer therapy, antimicrobial, autoimmune, cardiovascular, neurologicalPotential immune modulation; need immune safety profiling[69, 70]Stem cellGelatin nanogelsVarious therapeuticsTumor homing via chemokine gradientsTumor therapy, tissue targetingLimited targeting specificity[71, 72]Cancer cellPLGA, Fe₃O₄–DOX, Zr-based Pt(II) porphyrin MOFDOX, ICG, immune adjuvants, paclitaxelHomotypic tumor targetingChemotherapy, PDT/PTT, immunization, MRI contrastResidual DNA/RNA, oncogenic content (mitigated via purification/nuclease treatment)[73, 74]Hybrid (RBC–cancer, RBC–platelet)Hollow mesoporous CuS, PLGADOXCombined immune evasion & homotypic / platelet targetingChemo-photothermal therapy, enhanced multifunctional targetingMembrane fusion may dilute key proteins; size & charge variations affect pharmacokinetics[75, 76] Overview of different cell-membrane–coated nanoparticle systems, including membrane sources, and their corresponding therapeutic and diagnostic applications Overview of current biomimetic toolkit, including source cell types, fabrication strategies, membrane protein functions, and delivered cargoes. Adapted from the reference [77] under Creative Commons Attribution 4.0 (CC BY 4.0) Platelet membrane-coated NPs (PMNPs) Platelet membrane-coated NPs are reported to retain key platelet-associated membrane proteins and exhibit platelet-like functions, including immunocompatibility, selective adhesion, and long circulation. Similar to RBCNPs, CD47 on platelet membrane contributes to immune evasion by reducing macrophage uptake [78]. PMNPs specifically adhere to pathogens via bacterial surface proteins or bridging molecules, enabling targeted antimicrobial therapy. They also recognize and interact with damaged vasculature, inflamed endothelium, and tumor tissues through surface proteins such as GPIbα, GPIa/IIa, GPVI, GPIIb/IIIa, α6β1 integrin, αIIbβ3 integrin, and P-selectin. These characteristics permit PMNPs to deliver therapeutics efficiently targeted regions by improving drug efficacy but challenges of preserving bioactivity persists for large-scale production [79–81]. Platelet membrane-coated NPs have highlighted their ability to selectively adhere to damaged vasculature and tumor tissues via platelet-specific receptors, leading to improved targeting but variability in platelet source and scalability are major limitations for its clinical translation [82]. Cancer cell membrane-coated NPs (CCNPs) Cancer cell membrane-coated nanoparticles CCNPs are designed to exploit cancer cell-derived membrane components through partial preservation of immune evasion and homotypic targeting capabilities. CD47 overexpression enables immune evasion, while cancer cell adhesion molecules (CCAMs), including selectins, cadherins, integrins, immunoglobulin superfamily proteins, and CD44, mediate homotypic tumor targeting. Tumor-associated antigens such as Thomsen–Friedenreich glycoantigen (TF-Ag), which interacts with galectin-3, further enhance tumor-specific aggregation. CCNPs demonstrate substantially higher homologous cellular uptake compared with RBCNPs and uncoated NPs, with reduced off-target accumulation in organs like liver and kidney [83, 84]. CCNPs achieve enhanced homologous targeting and immune evasion, resulting in superior tumor accumulation and therapeutic efficacy; however, concerns related to tumor-derived membrane safety, potential immunogenicity, and heterogeneity of cancer cell sources pose significant challenges for their broader clinical application [22]. Macrophage membrane-coated NPs (MNPs) Macrophage membrane-coated nanoparticles (MNPs) are reported to mimic certain macrophage functions, depending on the extent of membrane protein retention and functional integrity, including immune evasion, site-specific targeting, and pathogen recognition. In studies, cell membrane source, such as membranes derived from immortalized macrophage cell lines (RAW 264.7, J774A.1) or from human monocytic THP-1 cells differentiated into macrophage-like cells, as well as primary human monocyte-derived macrophages (HMDMs) isolated from peripheral blood are used, to ensure biocompatibility [7, 85]. Several preclinical studies have reported that MNPs can achieve reduced clearance without eliciting significant unintended immune activation, as measured by minimal elevation of pro-inflammatory cytokines and lack of complement overactivation following systemic administration in murine models. Also, histopathological studies of treated animals did not indicate tissue level injury or immune dysregulation, indicating immune compatibility of these biomimetic systems [86]. Over 30% of MNPs lies in circulation after 24 h, whereas uncoated NPs were nearly entirely removed by phagocytosis [87]. MNPs exhibits improved antitumor effects while loading with chemotherapeutic agents like doxorubicin (DOX). Phagocytic clearance is reduced by MNPs and increased tumor endothelium recognition properties leads to increased accumulation in tumor regions. MNPs have also been used in photodynamic therapy [88]. They are able to reprogram protumoral M2-like macrophages into antitumoral M1-like phenotype preventing primary tumor growth and generating abscopal effects on malignant tumor sites [89]. By leveraging pattern recognition receptors (PRRs) on its surface MNPs membranes can recognize pathogen-associated molecular patterns (PAMPs), bind endotoxins (lipopolysaccharides LPS), and sequester cytokines without triggering harmful inflammatory cascades [90]. For example, macrophage membrane-coated NPs have been used to neutralize bacterial toxins in sepsis models, reduce proinflammatory cytokine level and inhibit bacterial dissemination. MNPs are capable of delivering antiretroviral or antiviral agents directly to viral infection sites, enhance drug retention, and neutralize cytokine as demonstrated in HIV and SARS-CoV-2 models. In leishmania, macrophage membrane-coated NPs selectively deliver antiparasitic drugs to infected macrophages [91]. MNPs interact with inflamed vascular sites due to presence of integrins (alpha4 and beta1) receptors on macrophage membrane in cardiovascular that identify VCAM-1 of activated endothelial cells. Membranes of THP 1 derived macrophages have been shown to have increased targeting in atherosclerosis models [92]. Exosomes produced by macrophages, especially by anti-inflammatory M2 macrophages have been utilized in delivery of heme biosynthesis modulators or small molecules, resulting in a dramatic decrease in aortic lesions and chronic vascular inflammation. The application in neurology takes advantage of natural capability of macrophages to traverse blood-brain barrier (BBB). Macrophage membrane-coated NPs and exosomes are used to deliver neuroprotective agents such as catalase, nerve growth factor, or small molecules to treat neurodegenerative diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), and spinal cord injury (SCI). These MNPs can reduce oxidative stress, inhibit proinflammatory signaling pathways, promote neuron survival, and enhance drug delivery to target neurons or microglia. In glioma models, MNPs loaded with chemotherapeutics improve transcytosis across the endothelial barrier, enhance tumor uptake, and extend survival [93–95]. MNPs are also highly effective in autoimmune and inflammatory diseases. In rheumatoid arthritis (RA), macrophage membrane-coated NPs target inflamed synovial tissues via interactions between MAC-1, CD44, and endothelial adhesion molecules (P-selectin, ICAM-1). Therapeutics loaded into these NPs (tacrolimus, glucocorticoids, or plasmid DNA) encoding IL-10, exhibit prolonged retention at inflamed sites, reduce proinflammatory cytokine production, and improve clinical outcomes. Similarly, in ulcerative colitis, pancreatitis, osteoarthritis, and allergic asthma, MNPs or macrophage-derived exosomes deliver drugs, siRNA, or nanozymes to inflamed tissues, utilizing ROS-responsiveness or pH-sensitivity for controlled release while minimizing systemic toxicity [7, 96]. Hybrid cell membrane-coated nanoparticles (HCMNs) Hybrid cell membrane-coated NPs combine membranes from multiple cell types to integrate complementary functions, including immune evasion, prolonged circulation, and targeted delivery. HCMNs expand the therapeutic versatility of monotypic cell membrane-coated-NPs [97]. RBC–platelet HCMNs Combination of RBC and platelet membranes enables both immune escape and targeting of inflammatory sites. RBC–platelet HCMNs demonstrate prolonged circulation times (51.8 h) compared with RBCNPs (42.4 h) and PMNPs (38.3 h), along with improved tumor targeting and photothermal conversion efficiency in photothermal therapy. These findings are primarily derived from preclinical murine models, where circulation half-life is typically assessed using fluorescence or radiolabel-based pharmacokinetic analysis under controlled dosing conditions; however, variations in particle size and surface charge across studies may influence comparative outcomes [98]. These NPs simultaneously absorb bacterial toxins, adhere to pathogens demonstrating its potential antibacterial applications [83]. Possible safety risk of platelet membrane-coated systems especially possibility of unwanted platelet activation, coagulation, or thrombosis cannot be ruled out. Recent reports show that these risks can be addressed by properly engineered platelet membrane-coated nanoparticles that can regulate platelet signaling pathways; such as inhibition of platelet activation by thrombin and inhibition of downstream Syk signaling preventing formation of neutrophil extracellular traps (NET) and inflammatory amplification. Functional analysis of murine models of acute lung injury revealed that these nanoparticles did not induce an excessive response of platelets but rather inhibited neutrophil infiltration. These results indicate that platelet membrane-coated nanoparticles can be designed to control targeting ability and hemostatic action at minimum risk of thrombogenicity and maximum therapeutic effect [99]. Erythrocyte–cancer cell HCMNs Erythrocytecancer cell HCMNs utilize homotypic targeting characteristics of cancer cell membrane whilst taking into account long circulation of RBC membranes. These HCMNs increase tumor accumulation, evade immune elimination, and increase therapeutic efficacy in phototherapy (PTT, PDT) and anticancer drug delivery. They can be used as tumor vaccines by loading the tumor related antigens in splenic antigen presenting cells, which triggers strong T-cell immunization without any side effects [100, 101]. Prussian blue nanoparticles coated with hybrid red blood cell-tumor cell membrane having mean diameter of 207 nm shown to retain membrane-associated proteins effectively in murine tumor model. In vivo study demonstrated high tumor accumulation within 10 min after irradiation leading to tumor inhibition rate of 93.56% without adverse profiles [102]. Biosafety issues especially potential presence of any residual intracellular components like fragments of DNA, RNA and oncogenic biomolecules are of concern. Recent research underlines membrane isolation procedures to reduce such risks with the help of multistep purification procedures. The cancer cells are usually subjected to hypotonic lysis and then subjected to the differential and density-gradient centrifugation to eliminate nuclei, cytosolic and other intracellular organelle proteins, and provide purified membrane fractions that are mostly free of nuclear and mitochondrial components. Such purification processes are usually supplemented with numerous washings, and sometimes enzyme treatments (nuclease digestion) to further eliminate remaining nucleic acid [103]. Experimental validation through SDS-PAGE and Western blotting is performed, in which membrane-coated NPs retain membrane-specific proteins and do not contain intracellular markers such as histone H3 and cytochrome c, which confirm successful removal of nuclear and mitochondrial components. Moreover, physicochemical characterization contributes to successful membrane coating without intracellular components contamination [73]. Leukocyte–cancer cell HCMNs (LCMs) LCMs combine immune evasion capabilities of leukocytes with tumor-targeting characteristics of cancer cells. These hybrid membranes demonstrate superior accumulation in tumor tissues (up to 9.3-fold higher as compared to controls) and improve drug delivery efficiency. They show immunotherapy strategies regulating parent cell antigen profiles to improve tumor clearance. To assess targeting efficiency and circulation behavior in vivo, standardized tumor models are employed but variations in experimental design and nanoparticle physicochemical properties can lead to variability in results of studies. They can be used in delivery of cancer therapeutics, phototherapy, immunotherapy, neutralization of bacterial toxins, and high-level diagnostics [104]. Organic, ceramic, and hybrid biomimetic nanomaterials Organic biomimetic nanomaterials Organic biomimetic nanomaterials use molecular self-assembly of proteins and peptides. The NPs nucleation, growth and hierarchical organization is regulated by solid or metal-binding sequences. Peptoids are biomimetic polymers of high chemical stability and adjustable amphiphilicity being customizable building blocks with functionalities [105, 106]. Ceramic biomimetic nanomaterials Ceramic scaffolds are porous, cancellous scaffolds are inspired by cancellous bone which offer structural support, where tissue ingrowth can occur with biological functionality. Challanges in regular tissue development and sufficient mechanical strength persists. They have been shown to be effective in dentistry where peptide-mediated remineralization with amelogenin or PAMAM dendrimers promotes remineralization of enamel [107, 108]. Hybrid biomimetic nanomaterials Hybrid biomimetic nanomaterials combine functional components at organic–inorganic interfaces, including bioinspired catalysts, cellulose–plant extract composites for antimicrobial applications, bamboo–hydrogel actuators responsive to near-infrared light, and magnetically or thermally triggered composite soft actuators [109]. Membrane-camouflaged NPs, particularly polymeric systems cloaked with erythrocyte, cancer cell, macrophage, or leukocyte membranes, are examples, enhancing drug delivery, detoxification, and inflammatory disease therapy [5, 109]. Hybrid BNMs also include biomimetic ceramic–polymer composites achieved via HAP regeneration using chitosan–maleic acid matrices or chitosan–alumina composites [110]. Fluorescence-quenching assays have shown that even partially coated NPs can enter tumor cells through cooperative aggregation mechanisms. In inflammatory disease therapy, leukosomes formed by integrating phospholipids with leukocyte membrane proteins enable targeted delivery to inflamed endothelium, while ROS-responsive macrophage membrane-coated NPs evade phagocytosis and suppress pathological cell proliferation [89]. These developments highlight emergence of biomimetic nanoceramics and membrane-coated organic/inorganic NPs as promising platforms for tissue engineering, dentistry, drug delivery, immunotherapy, photomedicine, and anti-inflammatory treatments. Nanoemulsion-based biomimetic nanocarriers The recent development of nanoemulsion-based biomimetic nanocarriers as an extension of hybrid biomimetic systems is based on the high loading capacity and physicochemical stability of nanoemulsions combined with the biological functionality of cell membrane coatings. Secondary oil-in-water nanoemulsions (SNEs) as effective cores to entrap lipophilic therapeutic agents, and biomimetic membrane coatings based on immune or cancer cells give them a targeting specificity and improved interactions with cells. As an example, monocyte- and macrophage-derived membrane-coated nanoemulsions (NEsoSomes) have shown better absorbed in inflamed endothelial models, and macrophage-like membrane coats have been shown to be readily internalized than monocyte-coated and uncoated nanocarriers, demonstrating their potential in vascular inflammation targeting [111]. Glioblastoma cell membranes have been successfully integrated into nanoemulsion surfaces to form stable and membrane-camouflaged nanocapsules with conserved morphology, biocompatibility and effective cellular uptake without cytotoxicity. These highlight the importance of nanoemulsion-based biomimetic system which offer multifunctional platform with the ability to co-deliver hydrophobic cargo and bioactive surface signals [112]. Design principles for biomimetic nanoparticles The design of biomimetic (BioM) NPs begins with identifying specific cellular or membrane-mediated function to replicate, which determines source cell for membrane extraction. After selecting biological function, decisions regarding therapeutic cargo and desired release profile dictate whether a synthetic lipid backbone or a drug-encapsulating NPs core is required [113–115]. Membrane extraction protocols including hypotonic lysis and differential centrifugation with aim to maximize yield and purity. Top-down or bottom-up approaches are employed (Fig. 4). Top-down approach follows downsizing of particles while preserving membrane complexity, whereas bottom-up approach control over core-to-protein ratios and particle size. BioM are then purified using centrifugation, dialysis, or more advanced techniques like tangential flow filtration. Characterization involves physicochemical analyses (size, polydispersity, morphology) and biomimetic assessments (protein presence, orientation, and retention), ensuring functional and application-specific NPs [116]. Top-down and bottom-up approaches for preparing biomimetic nanoparticles (BioM NPs). Top-down: (A) Cell membrane–coated NPs are produced by lysing cells (via sonication, freeze–thaw cycles, or hypotonic treatment), followed by membrane isolation using DGU, ultracentrifugation, or medium-speed centrifugation. Membranes can be further modified using streptavidin beads to attach biotinylated peptides. The purified membrane is then wrapped onto NPs cores by co-extrusion or sonication. (B) ACDVs can be generated through: (1) manual extrusion through filters of decreasing pore size, (2) centrifugation-assisted extrusion for large-scale production, (3) microfluidic cell-fragmentation, (4) nitrogen cavitation, or (5) cytoskeleton-disrupting agents that induce membrane blebbing and ACDV formation. Bottom-up: (A) In thin-film hydration, lipids dissolved in organic solvent are dried into a thin film, then rehydrated with membrane proteins and cargo to form MLVs or LUVs, which can be downsized into SUVs. (B) Biomimetic liposomes can also be generated by microfluidic mixing of lipids (in a miscible solvent) with cellular proteins and cargo (in aqueous phase). Adapted from the reference [113] under Creative Commons Attribution 4.0 (CC BY 4.0) Applications in cell-based therapeutics Biomimetic NPs in cancer therapy Cancer therapy continues to face critical challenges such as limited drug specificity, systemic toxicity, and poor tumor penetration. Integrating nanotechnology into conventional modalities like chemotherapy, radiotherapy, surgery, hyperthermia, and immunotherapy has improved outcomes by enabling better imaging resolution, more accurate residual tumor detection, and efficient drug delivery. Biomimetic (BioM NPs) offer additional advantages because their cell-mimicking surfaces promote biological compatibility, prolonged circulation, and targeted tumor accumulation [117]. Gene-editing and immune-modulatory nanoplatforms for breast and cervical malignancies are enhanced by nano-enabled delivery strategies. These platforms combine therapeutic and diagnostic functionalities in a single structure. Advanced BioM NP systems (tumor-cell membrane-coated polydopamine NPs) enable chemo-photothermal therapy, while macrophage membrane-camouflaged iron-poly(tannic acid) NPs allow for MRI imaging combined with pH-responsive chemotherapy. PEGylated liposomes demonstrate prolonged systemic circulation and reduced macrophage uptake in glioblastoma [118–120]. Passive targeting Passive targeting takes consist of leaky vasculature, inadequate lymphatic drainage, thick interstitium and high intratumoral pressure. NPs are concentrated preferentially at tumor sites through an enhanced permeability and retention (EPR) effect. These advantages are enhanced by BioM NPs whose biologically inspired surfaces enhance circulation time and tumor ingress. The half-life can be increased by surface modifications. Significant passive targeting vehicles use iron-modified mesoporous polydopamine NPs to combination of MRI, chemotherapy, and photothermal therapy to avoid immune clearance [120, 121]. Heterogeneity lies in EPR effect in different tumor types and among individual patients. Low vascular permeability of some tumors, high interstitial fluid pressure which impedes NP extravasation and active stromal barriers that inhibit deep tissue penetration are limitations associated with this effect while considering therapeutic deliveries [122, 123]. Research indicates that some tumors have low EPR responsiveness resulting into low amounts of NP accumulation and low therapeutic effects (pancreatic and desmoplastic tumors). Idiosyncratic passive targeting effectiveness in clinical environment may be caused by variations in tumor microenvironment, vascular density and perfusion between patients and complementary techniques such as ligand mediated active targeting or stimuli responsive release systems may be required to increase delivery precision and therapeutic efficacy [124, 125]. Active targeting Active targeting entails functionalization of BioM NPs using ligand antibodies, aptamers, peptides, amino acids or small molecules. These selectively target overexpressed receptors on cancer cells and increases intracellular uptake. Hybrid NPs decorated with folic-acid, dual-ligand chitosan NPs to EGFR and glycan receptors, and trastuzumab-modified ZIF-8 nanocarriers as systems to target HER2-positive cancers have been shown to have better tumor accumulation and cytotoxicity. Systems as trastuzumab-modified ZIF-8 nanocarriers for HER2-positive cancers, dual-ligand chitosan NPs targeting EGFR and glycan receptors, and folic-acid-decorated hybrid NPs have demonstrated superior tumor accumulation and cytotoxicity. Difficulties such as heterogeneity of receptors, stability of ligands, immune detection, and conjugation on global scale continue [126, 127]. Stimuli-responsive BioM NPs for controlled cancer drug release Biomimetic NPs that respond to stimuli release therapeutic cargo selectively in response to specified signals that include acidic microenvironment pH, high temperature, redox gradient and enzymes overexpression. This allows delivery of drugs to targeted sites and less systemic toxicity. When exposed to low pH, structural changes or chemical reaction to the exposure permit release of their therapeutic cargo, raising intratumoral levels of drugs with minimal exposure to normal tissue. Thermoresponsive NPs are programmed to discharge their loads in hyperthermic conditions that may occur naturally within the tumor, or by application of external heating. This is spatiotemporal control of drug release that enables precise delivery of drugs [128]. Enzyme-responsiveness leverage is an approach to selectively cleave NP structure, releasing encapsulated drugs depending on the activity of tumor-associated enzymes such as matrix metalloproteinases or quinone oxidoreductase-1. High site specificity is attained by endogenous activity of enzymes triggered by systems. The ROS-responsive NPs are subjected to structural changes in carrier allows release of chemotherapeutic agents to be controlled [129]. Nanogels of bupivacaine nanocrystals, thermoresponsive in combination with CuS NPs were found to exhibit photothermal release. Thermoresponsive liposomes loaded with Cisplatin increased cellular adherence and antitumor effects of Cisplatin during heat exposure in lung and breast cancer. ROS-receptive systems have been created of camptothecin considering tumor-specific oxidative conditions. The inability to regulate stable systemic circulation, under physiological conditions and reproducible large-scale production are key factors in translating these smart nanoplatforms into clinical practice [130, 131]. Diabetes treatment with biomimetic systems Single-compartmental vesicles Based on natural pancreatic β- cells, glucose-responsive vesicles have been designed to secrete insulin when glucose level rises. These systems involved use of pH-responsive nanovesicles that were loaded with insulin, glucose oxidase (GOx) and catalase (CAT). GOx transforms glucose into gluconic acid which reduces local pH and causes the disassembly of vesicles [132]. CAT is useful in breaking hydrogen peroxide, inhibiting cytotoxicity and preserving enzymatic activity. These vesicles attain high glucose rapid, pulsatile insulin release and normal glucose basal release. Incorporating thermoresponsive hydrogels, sustained glucose control in vivo can be achieved. Vesicles that are sensitive to hypoxia formed of amphiphilic polymers such as hyaluronic acid conjugated with 2-nitroimidazole (HA-NI). Oxygen in glucose oxidation results in formation of hypoxic microenvironment, which converts NI to a hydrophilic form and induces vesicle disassembly [133]. H₂O₂-responsive vesicles and dual-responsive vesicles combining hypoxia and ROS triggers enable rapid, biomimetic insulin release while minimizing oxidative damage. These vesicles can be integrated into microneedle-array patches for painless transdermal delivery or coated for oral absorption, mimicking physiological β-cell function [134]. Multicompartmental vesicles (artificial β-cells) Multicompartmental vesicles replicate spatial organization of natural β-cells. Inner nanovesicles act as insulin granules, while outer liposome vesicles mimic cytoplasmic membrane. Glucose sensors with membrane fusion machinery allow artificial β-cells (AβCs) to distinguish glucose levels and trigger insulin secretion dynamically. Subcutaneous administration achieves long-term glycemic control. Challenges includes enzyme sourcing, immunogenicity, and storage stability due to labile chemistries such as ketals and aryl boronate [135, 136]. Biomimetic cellular engineering systems Semibiological biomimetic systems Combining synthetic nanomaterials with cell membranes and other organnelles to form therapeutic carriers maintain biological activity of their origin cells. These systems acquire surface proteins, lipids and glycans of original cells. Coating of NPs by intact cell membranes confer specific benefits in immune evasion, circulation time, and tissue interactions. RBC membrane-coated NPs with long circulation times can avoid immune clearance, and biomimetic insulin delivery through glucose transporter proteins embedded into these membranes. Dual functionality prevents degradation of therapeutic payload in bloodstream and enables targeted release in diabetes treatment [116, 137]. Platelet membrane-coated nanogels innate tropism towards vascular injury or tumor tissue sites due to natural platelet homing to injured vasculature and their interaction with cancer cells, platelet membrane-coated drug-loaded nanogels result in increased localization of the nanogels in diseased sites. It enhances effectiveness of therapy as compared to traditional chemotherapy. Genetically engineered membrane vesicles e.g. PD-1 nanovesicles involve modification of cell membranes to express immune checkpoint receptors such as PD-1 to allow vesicles to selectively bind tumor-expressed PD-L1. This bivalent feature can block tumor microenvironment immunosuppressive signaling pathways and permit delivery of chemotherapeutic or immunomodulatory drugs directly to tumor site in biomimetic and highly targeted format [138, 139]. Whole-cell–based biomimetic systems Biomimetic systems based on whole-cells use inherent capabilities of living cells as a platform in high-tech drug delivery systems. These platforms use semibiological systems which mostly rely on cell membranes, and make full use of their natural capabilities to detect microenvironmental cues. It is possible to chemically conjugate these platelets with therapeutic agents like anti-PD-L1 antibodies. These platelets release their payload at targeted site, thereby improving therapeutic efficacy and off-target toxicity [139, 140]. Another novel application is Megakaryocyte-derived PD-1 platelets. In this case progenitor cells are megakaryocytes which are genetically engineered to generate platelets which express PD-1 on their surface. Such engineered platelets preserve normal biological platelet functions such as circulation and tissue homing and develop capability to selectively bind tumor cells that express PD-L1. The interaction reverse T-cell exhaustion, prevent tumor relapse, and also provide immunomodulatory drugs like cyclophosphamide for antitumor immune response. In addition to single-cell systems, cell cell hybrid strategies have also been developed. These are illustration of hematopoietic stem cells (HSCs), migrate to bone marrow loaded with antibody-decorated platelets to form hybrid complexes that may be used in targeted immunotherapy in marrow niches. This is highly effective in activating the immune response against acute myeloid leukemia (AML) offering highly localized therapeutic response. Whole-cell based biomimetic systems take advantage of dynamic and multifunctional nature with strong and adaptable platform of precision medicine and advanced therapeutics [141, 142]. Bioinspired signal networks for advanced therapies Artificial systems are under development that replicate cellular communication and allow drug carriers to sense, process and respond to biological cues (Fig. 5). Each liposomes, polymersomes, proteinosomes and coacervates have their own benefits when it comes to signaling, catalysis and release of molecules. These synthetic systems may communicate through direct contact, fusion or through chemical messengers tomimic natural cell networks [143]. Overview of multifunctional therapeutic applications of biomimetic nanoparticles. BioNPs enable treatment modalities like chemotherapy for improved tumor targeting; radiotherapy for radiosensitization and enhanced tumor ablation; gene therapy for delivery of genetic material; photothermal therapy and photodynamic therapy for generation of reactive ROS and localized hyperthermia; sonodynamic therapy involving ultrasound-triggered ROS production; immunotherapy through activation of immune responses and immune cell modulation with synergistic therapies combining multiple approaches for bio-imaging for real-time monitoring of treatment response. Adapted from the reference [144] under Creative Commons Attribution 4.0 (CC BY 4.0) Challenges associated with BioM NPs Despite their transformative potential, translating BioM NPs into clinical applications faces significant challenges. The production of cell membrane-coated NPs requires rigorous quality control at every stage. The source cells should be tested for sterility, endotoxin concentration, mycoplasma contamination, and authenticated against identity by means of the STR profiling or flow cytometry to confirm viability and functionality without contamination by pathogens. Membrane isolation and NP coating procedures should be standardized for ratio of membrane to NP, method of homogenization/extrusion, and the demonstration of protein retention. To assure the stability of NPs in storage, manufacturing processes require strict regulation of sterilization conditions (filtration, gamma irradiation), lyophilization, and presence of cryoprotectants (trehalose or sucrose), tangential flow filtration (TFF) and closed-system processing. The most frequent failures of these systems are membrane protein denaturation, aggregation and partial loss of functional targeting ligands during freeze-drying or filtration. Batch-to-batch reproducibility involves control of such variables like temperature, pH, formulation composition, drug loading efficiency, and release profiles and short- and long-term stability studies, endotoxin testing and in vitro functional assays to ensure reliability [83]. The in vivo behavior of cell membrane-coated NPs is not fully understood. This includes cellular uptake, intracellular trafficking and controlled release. Multiplex systems with several types of membrane do not necessarily yield corresponding improvements in targeting or circulation. Acquisition of membrane material can be difficult with autologous sources as donor-derived membranes have immunogenic risks. Maintaining functional protein and eliminating unnecessary parts is important and stability throughout storage is also limitation despite optimized cryoprotectants and lyophilization guidelines [145]. The requirements of compliance with GMP include validated quality control release tests (sterility, endotoxin, residual DNA/RNA, membrane protein integrity, particle size/zeta potential, encapsulation of the drug), and give batch release record complicating the translation process. Synthetic biology and nanotechnology offer possibilities to engineer genetically modified or organelle-based membranes with enhanced surface marks and multimodal activities. With maturation of these technologies, BioM NPs can become cornerstone of precision medicine offering highly targeted, multipurpose, and flexible therapeutic interventions [117, 145]. Future perspectives BioM NPs represent transformative frontier in modern medicine. These physical and physiological barreriers include mucosal layers, cellular membranes, blood-brain barrier and even placental barrier. The body is traditionally safeguarded by these barriers but drug delivery becomes limited. By imitating natural cells, BioM NPs offer ingenious strategy to overcome these defenses. Advanced BioM NPs have potential to travel through intricate tissues and access organs that are challenging to reach under normal conditions. This creates opportunities of accurate treatments in neurodegenerative disorders, brain tumors and other inaccessible pathologies. The other use is in transfection of genetic cargo. Although BioM NPs have ability to communicate with target cells naturally, loading them with DNA, RNA or gene-editing tools is difficult. Traditional loading methods, including electroporation or sonication, often compromise both integrity of the NPs and their payload. Emerging strategies, such as integrating isolated membrane proteins with customizable synthetic lipids, hold promise for safer and more efficient gene delivery. This approach could enable highly specific interventions at cellular and subcellular levels, expanding the therapeutic potential of BioM NPs (Fig. 6). Schematic illustration of the immunomodulatory effect of biomimetic nanoparticles in the immune microenvironment. BioNPs have direct immunomodulatory effects by interacting with immune cells to provide a variety of therapeutic effects, including: (1) Anti-infection, by capturing and neutralizing a wide range of pathogens, including Gram-negative bacteria (G-), Gram-positive bacteria (G +), and fungi; (2) Vaccination, by enhancing antigen presentation and promoting adaptive immune responses; (3) Anti-inflammation, by inhibiting the inflammatory network; (4) Anti-immunosuppression, by stimulating immune cells. Moreover, biomimetic NPs allow indirect immunomodulation through the use of targeted delivery vehicles of drugs, antigens, or other bioactive molecules by providing precise cell-specific targeting by interacting with the membrane to mediate effective immune responses. Such multifunctional immunomodulation forms the basis of the future of biomimetic NPs as a sophisticated therapeutic platform to address sepsis and other inflammatory diseases. Adapted from the reference [11] under Creative Commons Attribution 4.0 (CC BY 4.0) Protein corona formation, which occurs when BioM NPs adsorb plasma proteins in bloodstream, also plays a critical role in determining NPs behavior. Controlling protein corona formation could improve biodistribution. Hybrid cell membrane BioM NPs, which combine membranes or membrane proteins from multiple cell types are being developed to integrate unique advantages of prolonged circulation, improved tissue homing, and multifunctional therapeutic capabilities. By designing nanopores, such as engineered alpha-haemolysin and MspA pore, enzymatic modulation, and chemical modification of nanopores these BioM NPs can detect circulating single-molecule microRNAs, disease biomarkers, toxins and small molecules with single-molecule sensitivity. Cell-based sensors utilize receptor-expressing cells to sense chemical and odorant signals to monitor in real time. Conclusion The recent developments in biosensing and drug delivery fields provide natural cellular structures as biocompatible innovative carriers. Lipid bilayer sensors particularly with biological nanopores are sensitive, enabling analysis of small molecules, drugs, DNA, microRNAs, and proteins. Cell-based sensors use natural responsiveness of living cells to detect chemical cues in high fidelity by measuring optical or electrical outputs onto sophisticated platforms like microelectrode arrays. Although quality control, reproducibility, and clinical translation are challenges in integration of synthetic biology, genetically engineered cells, and organelle-derived membranes to provide personalized and precision therapeutics. The bioinspired systems emphasize through design imitation of nature with unmatched functionality. Lipid bilayer sensors, cell-based sensors, and membrane-coated NPs are future of diagnostics, therapeutics, and environmental sensors that will bridge the gap between biological complexity and technological advancement. Acknowledgements Not applicable. Author contributions YW: Data gathering, writing initial manuscript; LZ: writing manuscript, data curation; YZ: writing manuscript; review and finalization of the manuscript; LN: Supervision; critical review and finalization of the manuscript. All the authors listed meet the criteria for authorship as per the ICMJE guidelines, read the final manuscript and agree to publish this work. Funding This study was supported by Jilin Province Tianhua Health Charity Foundation (No. J2024JKJ006). Data availability No datasets were generated or analysed during the current study. Declarations Ethical approval and consent to participate Not applicable. This is a review paper and does not involve direct research on humans or animals. Consent for publication “Not applicable” as this manuscript does not contain data from any person. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.